| Date:Mar. 12 th , 2023 |
|---|
| Your Name:Mark T. Banovetz |
| Manuscript Title:Biomechanical Considerations for Graft Choice in Anterior Cruciate Ligament Reconstruction |
| Manuscript number (if known): AOJ-22-50(AOJ-2022-IGCAR-03) |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| | lectures, presentations, | XNone | | |
|------|---|--------------------------------|------------|--|
| | | | | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| _ | educational events | | | |
| 6 | Payment for expert | XNone | | |
| | testimony | | | |
| 7 | Support for attending | X None | | |
| , | Support for attending meetings and/or travel | None | | |
| | meetings and/or traver | | | |
| | | | | |
| | | | | |
| 8 | Patents planned, issued or | X None | | |
| O | pending | | | |
| | k-2 | | | |
| 0 | Daubiainabian arr - D-t- | V Nege | | |
| 9 | Participation on a Data | XNone | | |
| | Safety Monitoring Board or Advisory Board | | | |
| 10 | Leadership or fiduciary role | X None | | |
| 10 | in other board, society, | XNone | | |
| | committee or advocacy | | | |
| | group, paid or unpaid | | | |
| 11 | Stock or stock options | X None | | |
| | | | | |
| | | | | |
| 12 | Receipt of equipment, | X_None | | |
| | materials, drugs, medical | | | |
| | writing, gifts or other | | | |
| | services | | | |
| 13 | Other financial or non- financial interests | XNone | | |
| | | | | |
| | | | | |
| | | | | |
| DI - | Please summarize the above conflict of interest in the following box: | | | |
| Plea | ise summarize the above co | nflict of interest in the foll | owing box: | |
| N. | None. | | | |
| " | one. | | | |
| | | | | |
| | | | | |

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date:03/6/2023 |
|---|
| Your Name:Nicholas lung Kennedy |
| Manuscript Title: Biomechanical Considerations for Graft Choice in Anterior Cruciate Ligament |
| Reconstruction |
| Manuscript number (if known): AOJ-22-50(AOJ-2022-IGCAR-03) |
| |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|------|------------------------------------|--------------------------------|------------|
| | | | |
| | | | |
| 5 | Payment or honoraria for | None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| | | | |
| 7 | Support for attending | None | |
| | meetings and/or travel | | |
| | , | | |
| | | | |
| | | | |
| 0 | Datants planned issued or | None | |
| 8 | Patents planned, issued or pending | None | |
| | perioring | | |
| _ | Doublein stien en e Dete | News | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| Plea | ise summarize the above co | nflict of interest in the foll | owing box: |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| 1 | | | I |

| Please place an "X" next to the following statement to indicate your agreement: | | |
|--|--|--|
| X I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

Date: March 6, 2023

Your Name: Robert F. LaPrade MD, PhD

Manuscript Title: Biomechanical Considerations for Graft Choice in Anterior Cruciate Ligament Reconstruction

Manuscript number (if known): AOJ-22-50(AOJ-2022-IGCAR-03)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia | Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Time frame: pastYes | research grants from Ossur and Smith and Nephew |
| 3 | Royalties or licenses | Yes | royalties from Arthrex, Ossur, Smith and Nephew and Elsevier |
| 4 | Consulting fees | Yes | consulting fees from Ossur and Smith and Nephew |

| | Γ | T | |
|----|------------------------------|------|---|
| | | | |
| 5 | Payment or honoraria for | None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| | , | | |
| 7 | Support for attending | None | |
| , | meetings and/or travel | | |
| | lileetiligs allu/ol travel | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | Yes | has a patent with Ossur and Smith and Nephew |
| | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | Yes | on committees for AOSSM, AANA and ISAKOS |
| 10 | in other board, society, | 1es | off confinittees for AOSSIVI, AANA and ISAKOS |
| | I | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |

Please summarize the above conflict of interest in the following box:

| RFL receives research grants from Ossur and Smith and Nephew; is on committees for AOSSM, AANA and ISAKOS; |
|---|
| has a patent with Ossur and Smith and Nephew; receives consulting fees from Ossur and Smith and Nephew; and |
| receives royalties from Arthrex, Ossur, Smith and Nephew and Elsevier |

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

| Date:March 6 th 2023 |
|---|
| Your Name:Lars Engebretsen |
| Manuscript Title: Biomechanical Considerations for Graft Choice in Anterior Cruciate Ligament Reconstruction |
| Manuscript number (if known): AOJ-22-50(AOJ-2022-IGCAR-03) |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 Consulting feesX_None | |
|---|--|
| Xtone | |
| | |
| | |
| 5 Payment or honoraria forXNone | |
| lectures, presentations, | |
| speakers bureaus, | |
| manuscript writing or educational events | |
| 6 Payment for expertX_None | |
| testimonyNone | |
| testimony | |
| 7 Support for attending X_None | |
| meetings and/or travel | |
| Theetings and of cravel | |
| | |
| | |
| 8 Patents planned, issued or X None | |
| 8 Patents planned, issued orXNone | |
| pending | |
| | |
| 9 Participation on a DataX_None | |
| Safety Monitoring Board or | |
| Advisory Board | |
| 10 Leadership or fiduciary roleXNone | |
| in other board, society, committee or advocacy | |
| group, paid or unpaid | |
| | |
| 11 Stock or stock optionsXNone | |
| | |
| | |
| 12 Receipt of equipment,X_None | |
| materials, drugs, medical writing, gifts or other | |
| services | |
| | |
| 13 Other financial or nonXNone | |
| financial interests | |
| | |
| | |
| Digase summarize the above conflict of interest in the following how | |
| Please summarize the above conflict of interest in the following box: | |
| None. | |
| None. | |
| | |
| | |
| Please place an "X" next to the following statement to indicate your agreement: | |

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: March 22, 2023

Your Name: Gilbert Moatshe MD, PhD

Manuscript Title: Biomechanical Considerations for Graft Choice in Anterior Cruciate Ligament Reconstruction

Manuscript number (if known): AOJ-22-50(AOJ-2022-IGCAR-03)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Time frame: pastYes | 36 months Fellowship grants from Smith and Nephew |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | Yes | Consulting fees from Smith and Nephew and IBSA |

| г | Dayment or honoraria for | V Nano | |
|----|------------------------------|--------|--|
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | _XNone | |
| | testimony | | |
| | | | |
| 7 | Support for attending | XNone | |
| | meetings and/or travel | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | X None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | Yes | on committees for ISAKOS, Editorial Board JBJS and |
| | in other board, society, | | Arthroscopy |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | X None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

Please summarize the above conflict of interest in the following box:

| GM receives fellowship grant from Smith and Nephew; is on committees for ISAKOS; is on the Editorial Board for JBJS and Arthroscopy; receives consulting fees from IBSA and Smith and Nephew. | | | | |
|---|--|--|--|--|
| | | | | |
| | | | | |

Please place an "X" next to the following statement to indicate your agreement:

_ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.